As of Jan 17, 2025, Novartis AG Intrinsic Value is $138.2. This suggests it may be undervalued by 41.8% compared to its current price of around $97.5.
As of Jan 17, 2025, Novartis AG's Discounted Cash Flow (DCF) valuation estimates its share price at $156.6. This suggests it may be overvalued by 60.6% to its current price of around $97.5, using a discount rate of 6.8% and terminal growth rate of 3.0%.
Novartis AG is currently considered undervalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $138.2, compared to a market price of around $97.5. This suggests a potential undervaluation of 41.8%.